NUS

Nu Skin Enterprises to Discuss Company Strategy and Opportunities at ICR Conference

Retrieved on: 
Monday, January 8, 2024
Women, Alternative Medicine, Health, Vitamins, Supplements, Consumer, Fitness & Nutrition, Cosmetics, Retail, Webcast, Conference, Skin, NUS, Piramal Group

Nu Skin Enterprises Inc. (NYSE: NUS) today announced President and CEO Ryan Napierski and Chief Financial Officer James D. Thomas will present at the ICR Conference on Tuesday, Jan. 9.

Key Points: 
  • Nu Skin Enterprises Inc. (NYSE: NUS) today announced President and CEO Ryan Napierski and Chief Financial Officer James D. Thomas will present at the ICR Conference on Tuesday, Jan. 9.
  • Those wishing to access the event can visit the Nu Skin Investor Relations page at ir.nuskin.com .
  • The company will release fourth quarter and full year 2023 results after the market closes on Wednesday, Feb. 14.
  • The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m.

RxCell Announces $4,600,000 Investment from DMR Global Venture and Regenosis, Plans for Second Raise of $15,000,000 for IND Testing in Q4 2023

Retrieved on: 
Tuesday, December 5, 2023
Infectious Diseases, Finance, Clinical Trials, Professional Services, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, RPE, SERI, National University of Singapore, Notifiable disease, IND, Patient, USD, Investigational New Drug, Cell death, NUS, AMD, RPC, Retinal pigment epithelium, Cell, Name, National university, Pharmaceutical industry, Medical device

RxCell, a pioneering biotech company focusing on cellular therapeutics for age-related diseases, today proudly announces a $4,600,000 investment commitment from DMR Global Venture LLC and Regenosis.

Key Points: 
  • RxCell, a pioneering biotech company focusing on cellular therapeutics for age-related diseases, today proudly announces a $4,600,000 investment commitment from DMR Global Venture LLC and Regenosis.
  • Furthermore, RxCell is gearing up for a substantial second capital raise of $15,000,000 in Q4 2023.
  • The global Age-related Macular Degeneration (AMD) Market, an integral segment RxCell operates in, had a valuation of USD 7.47 billion in 2021.
  • Professor Xianmin Zeng, CEO of RxCell, remarked, "We're thrilled to align with DMR Global Venture and Regenosis.

NUS researchers develop an innovative and flexible method to study immune cell capabilities

Retrieved on: 
Monday, December 18, 2023
Cytokine, Research, Immune system, Protein, CSA, Multimedia, B cell, Infection, Biomedicine, Gene expression, Health, Workflow, National University of Singapore, Yale-NUS College, NUS, Engineering, CFSE, Biomedical engineering, Cell, Outline, Biology, National university, Nature Biomedical Engineering, Vaccine

SINGAPORE, Dec. 17, 2023 /PRNewswire/ -- Our body's immune system is a complex network of organs, cells, and proteins that work in synchrony to protect our bodies against infections caused by pathogens and fight against disease-causing changes in our body, such as the emergence of cancer cells. Cell-mediated cytotoxicity is one of such defence mechanisms carried out by the immune system that fights against foreign cells.

Key Points: 
  • "The novel methodology proposed by my team is highly selective in identifying the killer cells capable of efficiently eliminating a target cell.
  • During cell-mediated cytotoxicity, some immune cells can destroy foreign cells through cell lysis by releasing proteins that trigger a cascade of cellular processes that destroy foreign cells.
  • The researchers named this new method PAINTKiller (for 'proximity affinity intracellular transfer identification of killer cells').
  • The NUS researchers used an intracellular staining dye known as carboxyfluorescein succinimidyl ester (CFSE) to stain the foreign cells.

Nu Skin Opens New Manufacturing Facility in China

Retrieved on: 
Wednesday, November 29, 2023
NYSE, Investment, Local government, History, Skin, Nu Skin Enterprises, Fourth Industrial Revolution, Machine learning, NUS, Water, Fengxian District

PROVO, Utah, Nov. 29, 2023 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced the opening of its new manufacturing facility in Shanghai, China. Nu Skin has invested approximately $55 million in the new facility over the past few years, which will increase production capacity and supply chain responsiveness for the company in China and its other Asian markets.

Key Points: 
  • PROVO, Utah, Nov. 29, 2023 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced the opening of its new manufacturing facility in Shanghai, China.
  • "We have a 20-year history in Mainland China, and we continue to invest in our future in the region," said Ryan Napierski, Nu Skin president and CEO.
  • Steve Hatchett, Nu Skin executive vice president and chief product officer, added, "This state-of-the-art manufacturing facility quadruples the production capacity for Nu Skin in China.
  • Nu Skin Enterprises also has manufacturing facilities in the United States as part of its Rhyz Inc. subsidiary, a synergistic ecosystem of consumer, technology and manufacturing companies.

FPT Software Partners with Nanyang Polytechnic, Providing Students with International Tech Internships

Retrieved on: 
Thursday, November 9, 2023
Technology, Professional Services, Software, Data Analytics, University, Electronic Design Automation, IOT (Internet of Things), Education, Artificial Intelligence, Principal, Word-sense disambiguation, NUS, Nanyang, National University of Singapore, Standard Chartered, NTU, Nanyang Technological University, FPT Software, Memorandum of understanding, Multimedia, Nanyang Polytechnic, StarHub, SP Group, MNC, FPT Corporation, Student, Partnership, ComfortDelGro, FPT, National university, Signing ceremony, Singapore Airlines, Tutoring, Creative industries, CapitaLand

FPT Software, a global technology solution provider, has signed a memorandum of understanding (MoU) with Singapore’s Nanyang Polytechnic, providing internships for software engineering students at FPT’s Headquarters in Hanoi, Vietnam.

Key Points: 
  • FPT Software, a global technology solution provider, has signed a memorandum of understanding (MoU) with Singapore’s Nanyang Polytechnic, providing internships for software engineering students at FPT’s Headquarters in Hanoi, Vietnam.
  • Spanning over eight weeks, Nanyang Polytechnic students will join FPT Software Global Internship Programme, where they gain practical experience from the company’s international projects.
  • “FPT Software and Nanyang Polytechnic share many common goals and values centred around innovation and education.
  • With Vietnam emerging as a key player in tech innovation, this collaboration provides the software engineering students at Nanyang Polytechnic with a unique opportunity to explore Vietnam’s tech environment and gain hands-on experience in various technologies.

First BRST Draws Attendees from Over 80 Countries to Boost Science and Tech Collaboration

Retrieved on: 
Tuesday, November 7, 2023
Massachusetts Innovation & Technology Exchange, NUS, Belt, Innovation, National University of Singapore, Multilateralism, Science, technology, engineering, and mathematics, World Intellectual Property Organization, Global Innovation through Science and Technology initiative, Conference, Acquisition, Committee on Data of the International Science Council, Belt and Road Forum for International Cooperation, Development, National Medal of Technology and Innovation, BRST, Machine learning, National university, BRI, Nobel Prize, Belt and Road Initiative, Letter, Cryptocurrency, Management, Science, Physics, Xinhua News Agency

Chinese President Xi Jinping sent a congratulatory letter to the first BRST.

Key Points: 
  • Chinese President Xi Jinping sent a congratulatory letter to the first BRST.
  • Over 300 international guests from over 80 countries participated in the conference, including Nobel Prize winners, foreign academicians, experts, scholars, and presidents of well-known foreign universities.
  • The conference released the International Science and Technology Cooperation Initiative, advocating and practicing the concept of international science and technology cooperation that is open, fair, just and non-discriminatory, and working together to build a global science and technology community.
  • He foresees a future where robots specialized in data acquisition will create vast datasets for machine learning, significantly advancing material science.

NUS scientists develop innovative magnetic gel that heals diabetic wounds three times faster

Retrieved on: 
Thursday, October 19, 2023
Wuhan University of Technology, FDA, Engineering, NUS, Connective tissue, Yale-NUS College, Burns, Patent, Hydrogel, Keratinocyte, Orthopedic surgery, National University of Singapore, Agency, Sun, Diabetes, Infection, Nanyang Technological University, Wallace H. Coulter Department of Biomedical Engineering, Sengkang General Hospital, Cell, Fibroblast, Multimedia, Collagen, Quality of life, Tissue, Regeneration, Advanced Materials, Recurrence, Walking, National university, Agency for Science, Technology and Research, Blood, Overalls, Ulcer, Wound healing, Amputation, Patient, Biomedicine, Communication, Consultant, Biomedical engineering, Medical imaging, Electric motor, Nursing, Pharmaceutical industry, Dentistry, Research, Science

SINGAPORE, Oct. 19, 2023 /PRNewswire/ -- Diabetic patients, whose natural wound-healing capabilities are compromised, often develop chronic wounds that are slow to heal. Such non-healing wounds could cause serious infections resulting in painful outcomes such as limb amputation. To address this global healthcare challenge, a team of researchers from the National University of Singapore (NUS) engineered an innovative magnetic wound-healing gel that promises to accelerate the healing of diabetic wounds, reduce the rates of recurrence, and in turn, lower the incidents of limb amputations.

Key Points: 
  • Lab tests showed the treatment coupled with magnetic stimulation healed diabetic wounds about three times faster than current conventional approaches.
  • Furthermore, while the research has focussed on healing diabetic foot ulcers, the technology has potential for treating a wide range of complex wounds such as burns.
  • Chronic diabetic wounds such as foot ulcers (one of the most common and hardest to treat wounds) have therefore become a major global healthcare challenge.
  • While the magnetic wound-healing gel has shown great promise in improving diabetic wound healing, it could also revolutionise the treatment of other complex wound types.

EQS-News: Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'

Retrieved on: 
Tuesday, October 17, 2023
Partnership, NUS, National university, Drug development, MDAX, Polaris Partners, SCIENCE, Duke–NUS Medical School, Therapy, RESEARCH, National University of Singapore, FOR, Agency for Science, Technology and Research, Patient, Bayer, EVO, Frankfurt Stock Exchange, Academic Partnerships, SE, Growth, Evotec, Public sector, Duke University, University, LEAPS, POLARIS, Drug discovery, ISIN, Agency, AND, Pharmaceutical industry, Research, Science

“65LAB”, Evotec’s first academic BRIDGE in Asia, aims to advance drug discovery and the creation of new therapeutics companies in Singapore.

Key Points: 
  • “65LAB”, Evotec’s first academic BRIDGE in Asia, aims to advance drug discovery and the creation of new therapeutics companies in Singapore.
  • 65LAB was founded to establish a model of long-term partnership to foster future company growth and the development of Singapore’s biotech ecosystem.
  • 65LAB selects promising academic projects and invests up to US$ 1.5 m in each project over the course of 18-24 months.
  • The Board provides oversight and governance to 65LAB’s strategy and operations and includes Dr Wen Qi Ho, Therapeutics Lead, ClavystBio, Dr Christina Isacson, Partner, Lightstone Ventures, Dr Pei Sze Ng, Director, Leaps by Bayer, and Dr Kim Png, Principal, Polaris Partners.

G FUEL and CD PROJEKT RED Brave the Perils of Dogtown with "Cyberpunk 2077" Energy Drink Collab

Retrieved on: 
Friday, October 6, 2023
RPG, Night city, NUS, Antioxidant, G, PlayStation 5, PlayStation, Xbox Series X and Series S, Netflix, Cyberpunk, Box, Caffeine, Cyberpunk 2077, Pineapple, Tub, G Fuel, Video game, Diesel fuel

NEW YORK, Oct. 6, 2023 /PRNewswire/ -- G FUEL Energy celebrates CD PROJEKT RED's thrilling new Cyberpunk 2077 expansion, Phantom Liberty, with an energy drink collaboration based on a popular consumable item from the game: Naranjita Classic! G FUEL Naranjita is now available for pre-order in a Collector's Box and standalone 40-serving Tub at GFUEL.com while supplies last.

Key Points: 
  • G FUEL Naranjita is now available for pre-order in a Collector's Box and standalone 40-serving Tub at GFUEL.com while supplies last.
  • Fortunately, fans who get their hands on the G FUEL Naranjita Collector's Box will have energy and focus on their side.
  • Naranjita is G FUEL's second Cyberpunk collaboration, following up on G FUEL Immuno-Fluid inspired by the Cyberpunk: Edgerunners anime series on Netflix.
  • Like all G FUEL Energy Formula products, Naranjita is zero sugar and loaded with antioxidants from 18 different fruit extracts.

65LAB Launches in Partnership with Evotec SE and Backed by Leading Global Investors to Advance Drug Discovery and New Company Creation in Singapore

Retrieved on: 
Thursday, October 5, 2023
Transfer, Partnership, Public Service Enterprise Group, NUS, Duke–NUS Medical School, National university, Drug development, Development, Polaris Partners, Innovation, A*STAR, Therapy, Lightstone, University, National University of Singapore, Academic Partnerships, Patient, Bayer, Growth, Assistant professor, Duke University, Public sector, Drug discovery, STAR, Agency, Technology transfer, Tutoring, Pharmaceutical industry, Research, Evotec, Science

The first collaboration of its kind in Singapore, 65LAB was initiated by Lightstone Ventures with Evotec to leverage the global capabilities of its partners – including financing, networks, company creation, and drug development expertise -- to identify and accelerate the commercialization of the most promising research from top academic and R&D institutions in Singapore, the Agency for Science, Technology and Research (A*STAR), the National University of Singapore (NUS) and Duke-NUS Medical School (a collaboration between Duke University and NUS). 65LAB aims to combine Evotec's end-to-end integrated R&D platform and product development strength with Singapore's first-class academic and translational science, it's growing biotech infrastructure and capabilities to ultimately create breakthrough therapies with a global health impact.

Key Points: 
  • 65LAB was founded to establish a model of long-term partnership to foster future company growth and the development of Singapore's biotech ecosystem.
  • 65LAB selects promising academic projects and invests up to US$1.5 million in each project over the course of 18-24 months.
  • Upon completion, projects will be evaluated by 65LAB's board of global investors for further investment and the creation of new companies.
  • Dr. Thomas Hanke, EVP Head of Academic Partnerships at Evotec, said: "Singapore has multiple world-renowned institutions for basic research in the life sciences.